• Merck's Keytruda monotherapy significantly improved progression-free survival versus chemotherapy in Phase 3 KEYNOTE-C93, involving patients with dMMR advanced or recurrent endometrial cancer.
• Overall survival showed a favorable trend; follow-up remains ongoing.
• Severe treatment-related adverse events were less frequent with Keytruda; no new safety signals emerged.
• Results will be presented today at the ESMO Congress 2026; findings were published simultaneously in The Lancet.
• The findings support a potential chemotherapy-free treatment option; results will be submitted to regulators worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026620784) on October 26, 2026, and is solely responsible for the information contained therein.